The UK and US have concluded a key commercial pact that will maintain zero levies on UK medicine products entering the US market.
Key Provisions of the Accord
As part of the deal, the UK has committed to boost funding on pharmaceuticals through the NHS. This move guarantees that duties on these vital products will be held at zero for a timeframe of 36 months.
This agreement follows recent threats to hike import taxes on patented pharmaceutical products, with increases discussed as high as double the cost.
"This deal between the United Kingdom bolsters the international landscape for new treatments and establishes much-needed balance to American-British drug exports," an announcement noted.
Economic Significance
Drugs are one of the UK's largest exports to the US, which is clearly the primary buyer for leading UK drugmakers.
Export figures show that in the one-year period prior to the third quarter, the UK shipped medicines totaling £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This guarantee protects work, stimulates capital expenditure and facilitates the UK to emerge as a worldwide center for biotech and pharma," the Business and Trade Secretary stated.
Key British Pledges
The deal involves several notable commitments from the British government:
- Price Threshold Increase: The UK will raise the cost ceiling at which it deems new medicines to be unaffordable by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum pharmaceutical firms must return to the NHS to prevent overspending will be capped at fifteen percent. In the past, repayments exceeded twenty percent.
Industry Background
The pact follows a long-running dispute between the sector and the UK government over drug pricing and regulatory access.
This friction were heightened by claims that US patients were paying several times more for the equivalent treatments than patients in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or abandoned, while substantial expansions have been directed toward US facilities.
A senior figure publicly accepted that the NHS had to increase expenditure on treatments, noting that its expenditure on drugs had declined as a percentage of its resources over the last ten years.
